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The reported incidence of hyperkalaemia in
hospitalisedpatientsisbetween 1 and 10%. I Thevast
majority ofcases are related to patients prescribed
angiotensin converting enzyme inhibitors (ACE)
or angiotensin II receptor blockers (ARBs) in
conjunction with spironolactone with pre-existing
or new renal failure. Most other cases are related
to potassium supplementation and prescription of
diuretic/drugs with potassium-sparing properties.2
Itisthemostseriousofallelectrolyteabnormalities
as symptoms can be non-specific or absent, even
in severe hyperkalaemia, before causing cardiac
arrest.
The Cochrane Collaboration recently reviewed
the evidence forming emergency management of
hyperkalaemia.3 None ofthe studies ofclinically-
relevant hyperkalaemia reported on mortality or
cardiac arrhythmias. Studies were conducted in
convenience samples ofpatients and many ofthe
trialsweremethodologicallyflawed.Adverseevents
were rarelyreported and no serious adverse effects
were reported with any intervention. One single
episode of hypoglycaemia with insulin use was
reported in one study. These results reflect the fact
that most studies have been conducted in mildly
hyperkalaemic individuals and contrast with case
reports attesting to the deleterious cardiac effects
and adverse effects of treatment in patients with
severe hyperkalaemia.4'5
A decrease in the serum potassium is the most
frequently reported outcome in clinical trials.3
For this outcome intravenous insulin and glucose
and beta-2 agonists are effective therapies with
the combination being more effective than either
intervention employed alone. The evidence
supporting the use of intravenous bicarbonate is
equivocalandadministrationofpotassiumabsorbing
resinswill notlowerpotassiumacutely. Despitethe
lackofcompelling evidence to supporttheefficacy
ofintravenous bicarbonate and the potential to do
harm,theOxfordhandbookofAcuteMedicine(often
used byjunior staff) recommends the use of8.4%
sodium bicarbonate administered via central line!6
Haemodialysis represents the most effective but
also the most invasive approachto lowerthe serum
potassium.Althoughthereisnorandomisedevidence
tosupporttheuseofintravenouscalciumgluconate,
this measure is employed to stabilise the cardiac
membrane.3
Many of the studies reviewed by the Cochrane
collaboration reported before 1999. Since then the
incidenceofhyperkalaemiahassurged,inpartdueto
recommendations forthetreatmentofchronicheart
failure, presenting majormanagementproblems.7'8
These patients are often prescribed spironolactone
in addition to angiotensin converting enzyme
inhibitors and/or angiotensin II receptor blockade.
Simultaneous prescription ofNSAIDs, digoxin or
heparin, associated renal failure, diabetes mellitus
(typeIVrenaltubularacidosis),oldage,dehydration
andseverityofheartfailuregreatlymagnifytherisk
ofdeveloping severe hyperkalaemia.8 This clinical
scenario is likelytobe encounteredwith increasing
frequency by junior doctors on the acute medical
take. Given the serious cardiac outcomes, the
heterogeneityinexperttreatmentrecommendations
andthepotentiallyseriousadverseeffectsassociated
withtreatment, local guidance forthe management
of hyperkalaemia produced by Clinical Resource
Efficiency Support Team (CREST) is therefore
welcome.9
The guidelines and accompanying wall chart
(Figure) provide information on the classification
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ofhyperkalaemia, address commonaetiologies and
directpatientassessment andtherapeutic strategies
to safely and effectively manage hyperkalaemia.
The safe and effective use of insulin/dextrose in
the treatment ofhyperkalaemia is highlightedwith
particular emphasis placed on the requirement to
always use an insulin syringe and have a check of
volumebyaseniornursebeforeadministrationtothe
patient. The administration ofsodium bicarbonate
to lowerthe serumpotassium isnotrecommended.
Cardiacmonitoringismandatory.Howeveranormal
reading does not obviate the need for calcium
gluconate asthe ECGdoesnotalways demonstrate
findings even in severe hyperkalaemia. Caution
is required with the administration of calcium
gluconate ifthe patient is taking digoxin. Perhaps
the most important message for junior doctors
relates to early consultationwith senior colleagues
responsible forthe patient.
The guidance in the CREST document provides
clear and concise information to enable physicians
tosafelyandeffectivelymanagepatientspresenting
withhyperkalaemia. Iwouldurge alljuniordoctors
to use and follow this guidance and would like to
thank all the professionals who contributed to the
development ofthese guidelines.
REFERENCES
1. Moore ML, Bailey RR. Hyperkalaemia in patients in
hospital. NZMedJ 1989; 102(878): 557-8.
2. Acker CG, Johnson JP, Palevsky PM, Greenberg A.
Hyperkalemiainhospitalizedpatients: causes,adequacyof
treatment, andresults ofanattemptto improvephysician
compliancewithpublishedtherapyguidelines. ArchIntern
Med 1998; 158(8): 917-24.
3. Mahoney BA, Smith WA, Lo DS, Tsoi K, Tonelli M,
Clase CM. Emergency interventions forhyperkalaemia.
Cochrane Database Syst Rev 2005; 18(2): CD003235.
http:www.thecochranelibrary.com
4. Webster A, Brady W, Morris E Recognising signs of
danger: ECG changes resulting from anabnormal serum
potassium concentration. EmergMedJ2002; 19(1): 74-7.
5. DaveyM. Calciumforhyperkalaemiaindigoxintoxicity.
EmergMedJ2002; 19(2): 183.
6. Ramrakha P, Moore K. Oxford Handbook of Acute
Medicine 2nd Ed. Oxford University Press 2004:
pp384.
7. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A,
PerezA,PalenskyJ,WittesJ.Theeffectofspironolactone
on morbidity and mortality in patients with severe
heart failure. Randomized Aldactone Evaluation Study
Investigators. NEnglJMed 1999; 341(10): 709-17.
8. GrossP,PistroschF. Hyperkalaemia: again.NephrolDial
Transplant 2004; 19: 2163-66.
9. CREST. Guidelines for the treatment ofHyperkalaemia
in adults. Available from http://www.crestni.org.uk/
hyperkalaemia_booklet.pdf
C) The Ulster Medical Society, 2005. www.ums.ac.uk